| scholarly article | Q13442814 |
| P2093 | author name string | Anton A Buzdin | |
| Pieter Borger | |||
| Maxim I Sorokin | |||
| Andrew V Garazha | |||
| Anna A Emelianova | |||
| Denis V Kuzmin | |||
| Marianna A Zolotovskaia | |||
| Nikolay M Borisov | |||
| P2860 | cites work | Computational prediction of human metabolic pathways from the complete human genome | Q21092879 |
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| KEGG: kyoto encyclopedia of genes and genomes | Q24515297 | ||
| The Reactome pathway knowledgebase | Q24567743 | ||
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| GeneCards Version 3: the human gene integrator | Q24610308 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| PID: the Pathway Interaction Database | Q24656193 | ||
| Non-small cell lung cancer: current treatment and future advances | Q26740333 | ||
| Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer | Q26865075 | ||
| mTOR inhibitors in cancer therapy | Q28079129 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Ten years of pathway analysis: current approaches and outstanding challenges | Q29615564 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. | Q30798762 | ||
| Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays | Q31143550 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial | Q33877385 | ||
| Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. | Q33987206 | ||
| Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer | Q34168535 | ||
| Towards identification of true cancer biomarkers | Q34168702 | ||
| Drug resistance in cancer: an overview. | Q34437369 | ||
| Target identification and mechanism of action in chemical biology and drug discovery | Q34626974 | ||
| The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge | Q35066321 | ||
| Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies | Q35602185 | ||
| CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma | Q35871798 | ||
| Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers | Q35950111 | ||
| Temporary portal vein embolization is as efficient as permanent portal vein embolization in mice. | Q50725061 | ||
| Structure-based maximal affinity model predicts small-molecule druggability. | Q51925540 | ||
| Oncogenic Signaling Pathways in The Cancer Genome Atlas. | Q52602404 | ||
| DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. | Q52777528 | ||
| Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. | Q53286403 | ||
| Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases | Q55963652 | ||
| Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma | Q58761822 | ||
| Explaining the unexplainable: EGFR antibodies in colorectal cancer | Q83801494 | ||
| Targeting tyrosine kinases in cancer: the second wave | Q83854401 | ||
| Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs | Q89210692 | ||
| Testicular cancer: a reflection on 50 years of discovery | Q95434563 | ||
| Targeted cancer therapy | Q35953128 | ||
| Targeted cancer therapy--are the days of systemic chemotherapy numbered? | Q36174805 | ||
| Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia | Q36321006 | ||
| A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas | Q36496243 | ||
| A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation | Q36557305 | ||
| Trastuzumab: triumphs and tribulations | Q36832109 | ||
| Application of a new probabilistic model for mining implicit associated cancer genes from OMIM and medline | Q37175036 | ||
| In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. | Q37423763 | ||
| Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma | Q37463922 | ||
| COSMIC: somatic cancer genetics at high-resolution | Q37556877 | ||
| Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence | Q37826968 | ||
| Proteasome inhibitors: an expanding army attacking a unique target | Q37979388 | ||
| PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer | Q38236320 | ||
| Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). | Q38239630 | ||
| Disialoganglioside GD2 as a therapeutic target for human diseases | Q38325617 | ||
| Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety | Q38568548 | ||
| Bioinformatics Meets Biomedicine: OncoFinder, a Quantitative Approach for Interrogating Molecular Pathways Using Gene Expression Data | Q38604283 | ||
| Mathematical Justification of Expression-Based Pathway Activation Scoring (PAS). | Q38604285 | ||
| Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data. | Q38616209 | ||
| An overview of targeted cancer therapy | Q38650558 | ||
| COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer. | Q39302546 | ||
| Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors | Q41343608 | ||
| A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. | Q41701311 | ||
| Signaling pathways activation profiles make better markers of cancer than expression of individual genes. | Q41874902 | ||
| HMDB 4.0: the human metabolome database for 2018. | Q43212324 | ||
| Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas | Q44644664 | ||
| Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses | Q47152402 | ||
| The anti-tumorigenic activity of A2M-A lesson from the naked mole-rat | Q47215867 | ||
| Clinical development of mTor inhibitors for renal cancer | Q47737687 | ||
| Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. | Q50052905 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ggplot2 | Q326489 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs | |
| P478 | volume | 10 |
| Q93094401 | Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer |
| Q99571268 | Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments |
| Q89944453 | Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology |
| Q92921171 | Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology |
| Q64054373 | High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology |
| Q90288715 | Network-based method for drug target discovery at the isoform level |
| Q98945207 | Poly(ADP-ribose) polymerase inhibition: past, present and future |
| Q104073720 | Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations |
Search more.